ATTORNEY-CLIENT PRIVILEGED AND CONFIDENTIAL — DO NOT DISTRIBUTE
This communication is protected by the attorney-client privilege and the attorney work-product doctrine. It has been prepared at the direction of counsel for the sole purpose of providing legal advice to Penterra Pharmaceuticals Corp. This memorandum and its contents are strictly confidential and may not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.
MEMORANDUM
November 3, 2023
FROM: Audrey Zhou, Associate, and Jeffrey Park, Associate Calderwood & Harkness LLP 600 Lexington Avenue New York, NY 10022
TO: Margaret Tan, Executive Vice President & General Counsel Penterra Pharmaceuticals Corp. 480 Overlook Drive, Suite 700 Summit, NJ 07901
RE: Securities-Disclosure Obligations Arising from FDA Office of Prescription Drug Promotion Inquiry (OPDP-2023-1847) Concerning Zelvara® (trepivant sodium)
MATTER NO.: 1018-00002
I. Executive Summary
The purpose of this memorandum is to analyze the disclosure obligations of Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and related rules and regulations promulgated by the U.S. Securities and Exchange Commission (the "SEC"), arising from the Company's receipt of an inquiry letter dated October 12, 2023 (received at Penterra's corporate headquarters on October 16, 2023) from the Office of Prescription Drug Promotion ("OPDP"), a division of the Center for Drug Evaluation and Research ("CDER") within the U.S. Food and Drug Administration ("FDA"). The inquiry letter bears reference number OPDP-2023-1847 and concerns certain promotional materials disseminated by Penterra and its agents in connection with the marketing of Zelvara® (trepivant sodium, 75 mg and 150 mg oral tablets; NDA #214-837).
Penterra is a Delaware corporation whose common stock is listed and traded on the New York Stock Exchange ("NYSE") under the ticker symbol PTPH. As of late October 2023, Penterra's approximate market capitalization was $6.9 billion. The Company had total fiscal year 2022 ("FY 2022") revenue of approximately $2.18 billion. Zelvara® is Penterra's flagship therapeutic product, generating FY 2022 net revenue of $814.6 million, which represented approximately 37.4% of Penterra's total FY 2022 revenue. Through the first three quarters of fiscal year 2023 (Q1–Q3 2023), Zelvara® net revenue was $612.3 million, implying an annualized run rate of approximately $816.4 million. The product is, by a significant margin, the single largest revenue contributor in Penterra's portfolio, with particular dominance in the Company's CNS and pain therapeutics business segment.
Based on our analysis, we provide the following summary recommendations:
1. Form 8-K Filing. Penterra should file a Current Report on Form 8-K promptly — with a target filing date of November 6, 2023 — disclosing receipt of the OPDP inquiry as a material regulatory development under Item 8.01 ("Other Events"). Although there is no specific Form 8-K triggering item for receipt of an FDA inquiry letter, the materiality of the inquiry to the Company's principal revenue-generating product, coupled with SEC Staff guidance and enforcement precedent favoring prompt disclosure of material governmental or regulatory inquiries, makes voluntary disclosure under Item 8.01 strongly advisable.
2. Form 10-K Disclosure. Penterra should prepare appropriate risk-factor disclosures (Item 1A), legal-proceedings disclosures (Item 3), and Management's Discussion and Analysis ("MD&A") commentary (Item 7) for inclusion in Penterra's FY 2023 Annual Report on Form 10-K, which we understand is anticipated to be filed on or about February 28, 2024.
3. Auditor Coordination. The Company should coordinate with its independent registered public accounting firm, Meriden & Cole CPAs LLP ("Meriden & Cole"), regarding contingent-liability footnote considerations under Accounting Standards Codification Topic 450, Contingencies ("ASC 450"), for both the Q3 2023 quarterly period and the FY 2023 annual period.
4. Regulation FD Compliance. Penterra should take immediate steps to restrict internal discussion of the OPDP inquiry pending the Form 8-K filing so as to avoid any selective disclosure of material nonpublic information in violation of Regulation FD.
We note that this memorandum is confined to securities-disclosure obligations. It does not constitute advice on the merits of the FDA inquiry itself, including the strength or weakness of OPDP's stated concerns, the appropriate substantive response strategy, or the Company's potential exposure under the Federal Food, Drug, and Cosmetic Act. Those matters are addressed separately in our Preliminary Assessment Memorandum of even date, which has been transmitted under separate cover.
II. Factual Background
A. The OPDP Inquiry
On October 12, 2023, the FDA's Office of Prescription Drug Promotion issued an inquiry letter to Penterra Pharmaceuticals Corp. bearing reference number OPDP-2023-1847. The letter was received at Penterra's corporate headquarters in Summit, New Jersey, on October 16, 2023, and was promptly routed to the office of Margaret Tan, Executive Vice President and General Counsel. The reviewing officer identified on the letter is Dr. Carla M. Witherspoon, Pharm.D., Regulatory Review Officer, OPDP.
The inquiry concerns allegedly misleading promotional materials and sales representative communications disseminated by or on behalf of Penterra in connection with the marketing of Zelvara® (trepivant sodium), available in 75 mg and 150 mg oral tablet formulations, which was approved by the FDA on October 11, 2019 for the acute treatment of migraine with or without aura in adults.
The OPDP inquiry letter specifically identifies three promotional materials:
1. Digital Banner Advertisement (Material ID: ZVR-2023-BNR-044). This banner advertisement was placed on the MedLinkPro digital platform and ran continuously from April 15, 2023 through August 31, 2023 — a period of approximately four and one-half months. The banner featured the claim "Fastest Onset in Its Class," which OPDP characterizes as lacking adequate substantiation. Additionally, OPDP alleges that the banner omitted material risk information, specifically the hepatotoxicity risk identified in the Zelvara® prescribing information.
2. Physician Email Blast (Material ID: ZVR-2023-EML-019). This email communication was sent on June 7, 2023 to a distribution list of approximately 42,000 neurologists and primary-care physicians. OPDP alleges that the email featured a truncated y-axis bar chart that had the effect of visually exaggerating the efficacy differential between Zelvara® and a comparator product, thereby presenting a misleading impression of relative efficacy.
3. Sales Representative Detail Aid (Material ID: ZVR-2023-DA-007). This detail aid was approved by Penterra's internal Promotional Review Committee ("PRC") on March 22, 2023. OPDP alleges that the detail aid cited an unpublished, Penterra-funded retrospective chart review (Harmon et al., poster presentation, American Headache Society Annual Meeting, June 2022) without adequately disclosing (a) that the study was sponsored by Penterra, or (b) that the study lacked a control arm, thereby presenting the data in a misleading context.
The OPDP inquiry letter alleges that the cited promotional materials present potential violations of the following statutory and regulatory provisions:
• Section 502(n) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 352(n), which establishes requirements for the advertisement of prescription drugs, including the requirement that advertisements not be false or misleading and that they present a fair balance of information relating to effectiveness and side effects;
• 21 C.F.R. § 202.1(e)(5), which requires that prescription drug advertisements present a true statement of information in brief summary relating to side effects, contraindications, and effectiveness; and
• 21 C.F.R. § 202.1(e)(6), which prohibits advertisements that are false, lacking in fair balance, or otherwise misleading.
The original response deadline set forth in the OPDP inquiry letter was November 15, 2023 — thirty calendar days from the date of receipt. On November 1, 2023, Penterra, acting through Margaret Tan's office, submitted a request for an extension of the response deadline. As of the date of this memorandum, the extension request was pending. We note parenthetically that the extension request was subsequently granted by OPDP on November 8, 2023, extending the response deadline to January 15, 2024.
All three cited promotional materials were developed as part of a coordinated marketing initiative internally designated the "Clarity Campaign." The Clarity Campaign was designed and executed by Ridgeline Health Analytics LLC ("Ridgeline"), a promotional agency retained by Penterra, under a Statement of Work dated January 9, 2023 (total budget: $1.85 million). The Statement of Work was issued pursuant to a Master Services Agreement between Penterra and Ridgeline dated March 15, 2021, under which Ridgeline receives an annual retainer of $3.4 million for promotional strategy and execution services.
As of November 3, 2023, Penterra has voluntarily withdrawn all three cited promotional materials from circulation. The digital banner advertisement was removed from MedLinkPro; the physician email blast has not been re-sent; and the detail aid has been recalled from field sales representatives.
B. Penterra's Financial Profile and Zelvara® Revenue Significance
An understanding of Penterra's financial profile and the revenue significance of Zelvara® is essential to the materiality analysis that follows in Section IV of this memorandum. The key financial parameters are as follows:
• Total FY 2022 Revenue: $2.18 billion (as reported in Penterra's FY 2022 Annual Report on Form 10-K filed with the SEC on February 27, 2023).
• Zelvara® FY 2022 Net Revenue: $814.6 million, constituting approximately 37.4% of total FY 2022 revenue ($814.6 million ÷ $2,180 million = 37.39%).
• Zelvara® Q1–Q3 2023 Net Revenue: $612.3 million (as reported in Penterra's Quarterly Reports on Form 10-Q for the periods ended March 31, 2023, June 30, 2023, and September 30, 2023). Annualized, this implies Zelvara® revenue of approximately $816.4 million for FY 2023 ($612.3 million × 4/3 = $816.4 million), consistent with FY 2022 performance.
• Approximate Market Capitalization (October 2023): $6.9 billion, based on the closing price of PTPH common stock on the NYSE as of late October 2023 multiplied by shares outstanding.
• Employees: Penterra employs approximately 4,200 people globally, including approximately 680 field sales representatives responsible for detailing Penterra's products to healthcare professionals.
Zelvara® is, by any measure, the Company's single most important commercial asset. It is the largest revenue-generating product in Penterra's CNS and pain therapeutics portfolio, and no other product in the Company's pipeline or on-market portfolio approaches Zelvara® in revenue contribution. Any regulatory action or market development that materially constrains Penterra's ability to promote and sell Zelvara® would have a pronounced impact on the Company's consolidated financial results.
C. Engagement of Outside Counsel and Consultants
Calderwood & Harkness LLP was engaged by Penterra on October 30, 2023 to advise the Company on securities-disclosure obligations arising from the OPDP inquiry and to assist with the Company's broader response strategy. The engagement was established under matter number 1018-00002. The Calderwood & Harkness engagement team consists of:
• Leonard Cross, Partner (Responsible Partner)
• Nathaniel Bower, Partner (Billing Partner)
• Jeffrey Park, Associate (Lead Associate)
• Audrey Zhou, Associate (Working Associate)
The engagement letter, signed by Margaret Tan on behalf of Penterra, provides for a fee cap of $450,000 for the initial phase of work, which encompasses securities-disclosure advice, the preliminary assessment of the OPDP inquiry, and assistance with preparation of the substantive response to OPDP.
In addition to Calderwood & Harkness, the Company anticipates engaging two additional outside advisors:
• Whitfield Bauer & Associates LLP (Washington, DC), a boutique regulatory law firm, as regulatory co-counsel to assist with the preparation of the substantive response to OPDP and to provide specialized FDA regulatory expertise. The engagement terms are under negotiation as of the date of this memorandum.
• Tavrenis Stern Consulting Group LLC (Chicago, IL), a forensic consulting and e-discovery firm, to conduct a comprehensive review of Penterra's promotional materials, PRC meeting minutes, field sales representative training materials, and related documents in connection with the internal investigation. Tavrenis Stern has proposed a fixed fee of $87,500 for the initial document review and analysis phase.
III. Legal Framework for Disclosure Obligations
A. Form 8-K — Current Report Requirements
Under Section 13(a) and Section 15(d) of the Exchange Act, as implemented by SEC Regulation S-K and the instructions to Form 8-K, a publicly traded company is required to file a Current Report on Form 8-K to disclose certain specified events within four business days of their occurrence. In addition to the enumerated triggering events, Form 8-K provides two items under which a registrant may voluntarily disclose material information to the market.
Item 8.01 ("Other Events"). Item 8.01 of Form 8-K permits a registrant to report events that the registrant "deems of importance to security holders," even if the event does not fall within any of the other specifically enumerated items on Form 8-K. This is a voluntary disclosure vehicle, but it is the customary and appropriate mechanism for disclosing material governmental or regulatory inquiries, investigations, or proceedings that do not neatly fit within other triggering items. Disclosure under Item 8.01 results in the information being "filed" with the SEC (as opposed to "furnished"), which means the disclosure is subject to Section 18 liability under the Exchange Act and is incorporated by reference into Securities Act registration statements unless specifically excluded. Notwithstanding the Section 18 exposure, filing under Item 8.01 is the recommended approach here because the inquiry constitutes a material regulatory development that should be part of the Company's official SEC filing record.
Item 7.01 ("Regulation FD Disclosure"). Item 7.01 of Form 8-K provides a vehicle for a registrant to furnish information required to be disclosed under Regulation FD (discussed in greater detail in Section III.C below). If Penterra determines that any selective disclosure of the OPDP inquiry has occurred — for example, through conversations between senior management and analysts or institutional investors — furnishing information under Item 7.01 may be necessary to cure the selective disclosure. However, for the initial public disclosure of the inquiry, we recommend filing under Item 8.01 rather than furnishing under Item 7.01. Information furnished under Item 7.01 is not deemed "filed" and therefore is not subject to Section 18 liability, but it also does not carry the same weight in the Company's SEC filing record.
We also note that there is no specific Form 8-K triggering item that applies to the receipt of an FDA inquiry letter as distinguished from a formal enforcement proceeding, a governmental investigation, or the receipt of a Wells notice or similar communication. Item 1.01 (Entry into a Material Definitive Agreement), Item 2.06 (Material Impairments), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard), and Item 8.01 (Other Events) are the items most commonly considered in connection with regulatory developments. Of these, Item 8.01 is the appropriate vehicle for the present situation.
SEC Staff guidance and enforcement precedent strongly favor prompt disclosure of material governmental or regulatory inquiries or investigations, particularly where they relate to a company's principal revenue-generating product. In its 2011 CF Disclosure Guidance: Topic No. 2 (Cybersecurity) and subsequent Staff guidance, the Division of Corporation Finance has emphasized the importance of timely disclosure of material events that affect a registrant's business, even where the precise financial impact is uncertain. More directly, in a series of enforcement actions, the SEC has imposed penalties on pharmaceutical and life sciences companies that failed to timely disclose material FDA regulatory developments, including warning letters, clinical hold orders, and compliance-related inquiries, where the undisclosed information was material to investors' understanding of the company's financial condition and business prospects. While these enforcement actions typically involved more advanced stages of regulatory action (e.g., Warning Letters or clinical holds), the underlying principle — that material regulatory developments must be disclosed promptly — applies with equal force to the present inquiry given Zelvara®'s outsized contribution to Penterra's revenue.
B. Form 10-K — Annual Report Disclosure Requirements
Penterra's FY 2023 Annual Report on Form 10-K (anticipated filing date: February 28, 2024) will need to address the OPDP inquiry in several sections. The applicable requirements are discussed below.
Risk Factors (Item 1A). Regulation S-K Item 105 (formerly Item 503(c)) requires a registrant to disclose the "material factors that make an investment in the registrant or offering speculative or risky." The SEC's 2020 amendments to Item 105 reinforced the requirement that risk factors be specific and tailored to the registrant's particular circumstances, rather than generic or boilerplate. The OPDP inquiry creates a specific, realized risk relating to Penterra's promotional practices and regulatory compliance for its single largest revenue-generating product. Penterra's prior Form 10-K filings (including the FY 2022 10-K) contain generic risk factors regarding FDA regulatory risk and the potential for adverse regulatory actions. These existing risk factors should be updated in the FY 2023 10-K to disclose the specific OPDP inquiry and the risk that the inquiry could result in enforcement action, promotional restrictions, or other adverse consequences. The SEC has criticized registrants for failing to update generic risk factors to reflect specific, known risks, and doing so here would expose Penterra to potential SEC comment-letter scrutiny or, in a more adverse scenario, enforcement action.
Legal Proceedings (Item 3). Regulation S-K Item 103 requires disclosure of any "material pending legal proceedings, other than ordinary routine litigation incidental to the business." The instructions to Item 103 specify that the term "legal proceedings" includes "any material proceedings to which any director, officer or affiliate of the registrant, any owner of record or beneficially of more than five percent of any class of voting securities of the registrant, or any associate of any such director, officer, affiliate of the registrant, or security holder is a party adverse to the registrant or has a material interest adverse to the registrant." Importantly, the term encompasses administrative proceedings as well as judicial proceedings. Although the OPDP inquiry is styled as an inquiry rather than a formal administrative proceeding, and although OPDP has not initiated an enforcement action, the materiality of the inquiry to Penterra's business — involving allegations of misleading promotion of the Company's largest product — supports disclosure under Item 3. The SEC has taken the position in comment letters that inquiries and investigations that could reasonably lead to material administrative or enforcement proceedings should be disclosed, even if they are in a preliminary stage.
Management's Discussion and Analysis of Financial Condition and Results of Operations (Item 7). Regulation S-K Item 303 requires the registrant to discuss "any known trends or any known demands, commitments, events or uncertainties that will result in or that are reasonably likely to result in the registrant's liquidity increasing or decreasing in any material way" and "any known trends or uncertainties that have had or that are reasonably likely to have a material favorable or unfavorable impact on net sales or revenues or income from continuing operations." The OPDP inquiry introduces an uncertainty that is reasonably likely to have a material impact on Penterra's operations. Specifically, the Company must consider and discuss (a) the potential impact on Zelvara® revenue if promotional activities are restricted or modified as a result of the inquiry; (b) the costs of remediation, including corrective communications to healthcare providers, sales-force retraining, PRC process improvements, and promotional agency transition costs; and (c) outside counsel and consulting fees associated with the internal investigation and response preparation. Even if the ultimate financial impact is uncertain at the time of filing, the existence of the inquiry and its potential implications must be discussed.
Financial Statements — Contingent-Liability Footnote (ASC 450). The potential for contingent-liability footnote disclosure in Penterra's FY 2023 financial statements is discussed in detail in Section VI of this memorandum.
C. Regulation FD Considerations
Regulation FD (17 C.F.R. §§ 243.100–243.103), adopted by the SEC in August 2000, prohibits the selective disclosure of material nonpublic information by issuers to securities market professionals and certain security holders. Rule 100(a) of Regulation FD provides that whenever an issuer, or any person acting on its behalf, discloses material nonpublic information to any person described in Rule 100(b)(1) — including broker-dealers, investment advisers, institutional investment managers, investment companies, and holders of the issuer's securities under circumstances in which it is reasonably foreseeable that the holder will trade on the information — the issuer must simultaneously disclose that information to the public (in the case of intentional disclosure) or promptly thereafter (in the case of non-intentional disclosure).
The OPDP inquiry constitutes material nonpublic information. It has been known to Penterra's senior management since October 16, 2023, when the inquiry letter was received, and to a broader circle of Penterra employees and advisors since that date. As of the date of this memorandum, the inquiry has not been publicly disclosed. Care must therefore be taken to ensure that the fact or substance of the inquiry is not communicated to any person covered by Regulation FD prior to public disclosure via the recommended Form 8-K filing.
We recommend that Margaret Tan, in her capacity as General Counsel, immediately issue an internal directive restricting discussion of the OPDP inquiry pending the filing of the Form 8-K. The directive should be distributed to all members of Penterra's executive leadership team, the investor-relations function, and the commercial operations and marketing team. Particular attention should be given to Derek Foss, Vice President of Commercial Operations and Marketing, who oversees the Zelvara® promotional programs at issue and who may receive inquiries from trade media or industry contacts regarding Penterra's promotional activities. Additionally, any Penterra personnel who interact with securities analysts, institutional investors, or other market professionals should be specifically instructed not to discuss the OPDP inquiry until the 8-K has been filed with the SEC and the information is publicly available.
If any selective disclosure has already occurred — whether intentionally or inadvertently — Penterra must promptly disclose the information publicly, either by filing or furnishing a Form 8-K under Item 7.01 or by issuing a press release. We are not aware of any selective disclosure having occurred as of the date of this memorandum, but we recommend that Margaret Tan confirm this with the investor-relations team and with Derek Foss.
IV. Materiality Analysis
The threshold question for all of the disclosure obligations discussed in Section III is whether the OPDP inquiry is "material" within the meaning of the federal securities laws. Under the standard articulated by the Supreme Court in TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438, 449 (1976), and applied in the context of forward-looking information in Basic Inc. v. Levinson, 485 U.S. 224, 231–32 (1988), information is material if there is "a substantial likelihood that a reasonable shareholder would consider it important" in making an investment decision. This standard does not require that the information would, standing alone, change the outcome of the shareholder's decision, but rather that there is a substantial likelihood that it would be viewed as having "significantly altered the 'total mix' of information made available." TSC Industries, 426 U.S. at 449.
The SEC and the courts have recognized that the materiality determination involves both quantitative and qualitative considerations. SEC Staff Accounting Bulletin No. 99 ("SAB 99"), issued in 1999, provides guidance on the application of materiality in the context of financial-statement misstatements, but its framework is instructive in the broader disclosure context as well. SAB 99 emphasizes that a purely quantitative approach to materiality is insufficient and that qualitative factors — including the nature of the item, the circumstances in which the judgment is made, and the effect on compliance with regulatory requirements or contractual obligations — must also be considered.
A. Quantitative Materiality Assessment
The quantitative case for materiality is strong. Zelvara® is Penterra's single largest product, contributing $814.6 million in net revenue in FY 2022, which represented 37.4% of total FY 2022 revenue of $2.18 billion. Through the first three quarters of FY 2023, Zelvara® has generated $612.3 million in net revenue, on an annualized trajectory of approximately $816.4 million — essentially flat with FY 2022 performance and still representing a dominant share of Penterra's total revenue base.
Any regulatory action that restricts or materially alters Penterra's ability to promote Zelvara® — whether through a mandatory corrective action (such as a Dear Healthcare Provider letter), a restriction on certain promotional claims, or a broader enforcement action — could have a direct and measurable impact on Zelvara® prescription volume and, consequently, on the Company's net revenue and earnings. Given Zelvara®'s share of total revenue, even a single-digit percentage decline in Zelvara® revenue would represent a material impact on Penterra's consolidated financial results. For context, a 5% decline in Zelvara® annual revenue from the $816.4 million annualized run rate would represent approximately $40.8 million in lost revenue — a figure that, standing alone, would be material to Penterra's financial statements under conventional quantitative thresholds (typically 5% of pre-tax income or 0.5–1.0% of total revenue).
Moreover, the potential stock-price impact is significant. With an approximate market capitalization of $6.9 billion, even a modest percentage decline in Penterra's stock price in response to disclosure of the OPDP inquiry could represent hundreds of millions of dollars in lost shareholder value. Empirical research and market experience indicate that pharmaceutical companies routinely experience stock-price declines of 3–7% or more upon disclosure of material FDA regulatory actions affecting their principal products, with larger declines possible depending on the perceived severity of the regulatory risk.
Even without a formal enforcement action, the inquiry itself — if it became publicly known through channels outside Penterra's control, such as a Freedom of Information Act ("FOIA") request by a media outlet, a competitor's inquiry, or a whistleblower disclosure — could cause stock-price volatility. The risk of uncontrolled disclosure amplifies the quantitative materiality of the inquiry.
B. Qualitative Materiality Assessment
The qualitative factors weigh even more heavily in favor of materiality.
Nature of the Allegations. The OPDP inquiry alleges misleading efficacy claims and the omission of material risk information in Penterra's promotional materials for Zelvara®. These allegations go to the core of Penterra's commercial strategy for its most important product. The integrity of a pharmaceutical company's promotional practices is a matter of fundamental concern to investors, regulators, prescribers, and patients. Allegations of misleading promotion are among the most serious regulatory issues a pharmaceutical company can face, as they implicate not only FDA enforcement risk but also potential liability under the federal False Claims Act (31 U.S.C. §§ 3729–3733), the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b), and analogous state consumer-protection statutes.
Scope of the Promotional Activity at Issue. The three cited promotional materials were part of the Clarity Campaign, a coordinated, multi-channel marketing initiative. The scope of the promotional activity was substantial: the physician email blast alone reached approximately 42,000 neurologists and primary-care physicians; the digital banner advertisement ran on a major healthcare professional platform for approximately four and one-half months; and the detail aid was deployed to Penterra's field sales force of approximately 680 representatives for use in physician office visits. The breadth of dissemination heightens the regulatory significance of the inquiry and increases the potential scope of any corrective action that may be required.
Regulatory Escalation Risk. Although the current OPDP communication is styled as an inquiry or untitled letter — a lower tier of regulatory action than a Warning Letter — failure to respond adequately and in a timely manner could result in escalation to a Warning Letter, which is a more severe form of enforcement action that is posted publicly on the FDA's website and typically requires a formal corrective action plan. Beyond a Warning Letter, the matter could be referred to the Department of Justice ("DOJ") for potential civil or criminal prosecution, or to the Office of Inspector General ("OIG") of the Department of Health and Human Services for exclusion proceedings. While such escalation is not inevitable, the risk of escalation is a qualitative factor that a reasonable investor would want to consider.
Reputational Considerations. Penterra's standing with prescribers, payers, and patients is a critical intangible asset. If Penterra is found to have engaged in misleading promotional practices, the Company's reputation for scientific integrity and transparent communication with healthcare professionals could be damaged, with cascading effects on Zelvara® prescription rates, payer formulary status, and patient confidence. These reputational considerations are difficult to quantify but are undeniably material.
SEC Enforcement Risk. The SEC has brought enforcement actions against pharmaceutical companies for failure to timely disclose material regulatory inquiries and investigations. In SEC v. Severin & Co. (2004), the SEC charged a major pharmaceutical company with, among other things, failing to disclose material information regarding regulatory and competitive developments affecting its principal products. More recently, the SEC has brought enforcement actions under Section 13(a) of the Exchange Act against life sciences companies that delayed disclosure of material FDA regulatory actions. The risk of SEC scrutiny is heightened where, as here, the undisclosed inquiry relates to the company's primary revenue product and the company's stock trades on a major national securities exchange.
Internal Compliance Concerns. Our preliminary review — which is ongoing and will be supplemented in subsequent memoranda — has identified certain internal compliance concerns that add to the qualitative weight of the disclosure obligation. Specifically, we understand that the PRC approved the detail aid (Material ID: ZVR-2023-DA-007) on March 22, 2023 notwithstanding objections raised by Penterra's Medical Affairs department, and that there are indications that certain field sales representatives may have made claims beyond the scope of the approved detail aid in their interactions with prescribers. These internal compliance issues, if confirmed, could increase the severity of the regulatory outcome and the potential for enforcement action, further supporting the conclusion that the inquiry is material.
C. Conclusion on Materiality
Based on the foregoing quantitative and qualitative analysis, we conclude that the OPDP inquiry is material to Penterra's investors under the standard articulated by the Supreme Court in TSC Industries and Basic Inc. v. Levinson. The inquiry relates to promotional practices for a product that generates more than one-third of the Company's total revenue, involves allegations of misleading efficacy claims and risk-information omissions that go to the integrity of Penterra's core commercial strategy, and carries the potential for regulatory escalation, reputational harm, and financial loss.
The fact that the inquiry is preliminary and has not yet resulted in a Warning Letter, enforcement action, or monetary penalty does not diminish the disclosure obligation. SEC guidance and case law establish that the existence of a material inquiry or investigation must be disclosed regardless of its stage. In Galena Biopharma, Inc. (SEC enforcement action, 2016) and related proceedings, the SEC took the position that the pendency of a government investigation — even at an early or informal stage — constituted material information requiring disclosure where the investigation involved the company's principal commercial product and promotional practices. We see no principled basis for distinguishing the present situation.
Accordingly, we recommend that Penterra disclose the OPDP inquiry promptly through the filing of a Current Report on Form 8-K and that the Company prepare appropriate disclosures for its FY 2023 Annual Report on Form 10-K, as discussed in the following sections.
V. Recommended 8-K Disclosure
A. Timing
We recommend that Penterra file the Form 8-K by November 6, 2023. This target date is designed to ensure that the filing occurs within a reasonable period following the engagement of outside counsel (October 30, 2023), the completion of the initial legal assessment (this memorandum, dated November 3, 2023), and the voluntary withdrawal of the three cited promotional materials from circulation (completed November 3, 2023). Filing on November 6 — the next business day after the issuance of this memorandum — allows sufficient time for internal review and approval of the 8-K draft while ensuring prompt public disclosure.
We believe it is important that the filing precede any possible public disclosure of the inquiry through channels outside Penterra's control. OPDP inquiry letters are not routinely published on the FDA's website (unlike Warning Letters, which are posted publicly), but the letter could become publicly available through a FOIA request, a Congressional inquiry, a whistleblower complaint, or media reporting. Any such uncontrolled disclosure would deprive Penterra of the ability to frame the narrative and could trigger Regulation FD concerns if the information reaches securities market professionals before the general public.
B. Suggested Disclosure Content (Item 8.01)
We recommend that the Form 8-K contain the following disclosure under Item 8.01 ("Other Events"). The language below is a preliminary draft for discussion purposes and will require review and approval by Margaret Tan and other members of Penterra's senior management before filing:
On October 16, 2023, Penterra Pharmaceuticals Corp. (the "Company") received an inquiry letter dated October 12, 2023 (reference OPDP-2023-1847) from the Office of Prescription Drug Promotion ("OPDP") of the U.S. Food and Drug Administration ("FDA") regarding certain promotional materials for Zelvara® (trepivant sodium), 75 mg and 150 mg oral tablets, the Company's FDA-approved product for the acute treatment of migraine with or without aura in adults. The OPDP inquiry raises questions regarding the adequacy of certain promotional materials, including the substantiation of efficacy claims and the presentation of risk information.
The Company has voluntarily withdrawn the cited promotional materials and is cooperating fully with the OPDP inquiry. The Company has engaged outside counsel to conduct an internal review and prepare a response to the inquiry.
The Company is unable to predict the outcome of the OPDP inquiry or the timing of its resolution. While the Company believes that its promotional practices are in compliance with applicable law and regulations, there can be no assurance that the inquiry will not result in adverse regulatory action, including the issuance of a Warning Letter or other enforcement action. The Company does not currently believe that the inquiry will have a material adverse effect on its business, financial condition, or results of operations, although no assurance can be given in this regard.
Cautionary Statement Regarding Forward-Looking Statements: This Current Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company's current expectations and are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to differ include, but are not limited to, the outcome of the OPDP inquiry, potential regulatory actions by the FDA, changes in the Company's promotional practices, and the factors described in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
We note that the statement that the Company "does not currently believe that the inquiry will have a material adverse effect on its business, financial condition, or results of operations" should be included only if such belief is supportable at the time of filing. We recommend that this point be discussed with Margaret Tan before the draft is finalized. If, based on the internal investigation or other information, the Company is unable to make such a statement in good faith, the final sentence of the second-to-last paragraph should be modified or deleted.
C. Review and Approval Process
We propose the following review and approval process for the Form 8-K:
1. Draft Preparation. The initial draft of the 8-K will be prepared by Audrey Zhou and Jeffrey Park at Calderwood & Harkness and submitted to Leonard Cross for partner-level review.
2. Penterra Legal Review. Following partner review, the draft will be transmitted to Margaret Tan and Christine Holloway (Associate General Counsel, Securities and Compliance) for review and comment. We anticipate a single round of revisions.
3. Scientific Accuracy Review. We recommend that Dr. Rajeev Anand, Penterra's Chief Medical Officer, be given an opportunity to review the disclosure for scientific accuracy, particularly the description of Zelvara®'s approved indication and the characterization of the promotional materials. Dr. Anand's review should be limited to factual accuracy and should not extend to the legal analysis or disclosure strategy.
4. Investor Relations Coordination. In connection with the 8-K filing, Penterra's investor-relations function should prepare (a) a brief press release, if management deems one appropriate, to accompany the 8-K filing; and (b) a prepared Q&A document for use in responding to analyst or media inquiries following the filing. Calderwood & Harkness should review the press release and Q&A for consistency with the 8-K disclosure and compliance with the securities laws.
5. EDGAR Filing. Following final approval by Margaret Tan, the 8-K will be filed electronically via the SEC's EDGAR system. Penterra's EDGAR filing agent should be alerted to the anticipated filing date.
VI. Coordination with Meriden & Cole CPAs LLP — Contingent-Liability Considerations
A. ASC 450 (Contingencies) Analysis
Under ASC 450-20 (Loss Contingencies), a loss contingency must be evaluated to determine whether it requires (a) accrual in the financial statements, (b) disclosure in the footnotes without accrual, or (c) neither accrual nor disclosure.
Accrual is required when two conditions are met: (1) information available prior to issuance of the financial statements indicates that it is probable that a loss has been incurred as of the date of the financial statements, and (2) the amount of the loss can be reasonably estimated. At this early stage — November 3, 2023, approximately two and one-half weeks after receipt of the inquiry letter — it is premature to conclude that a loss is probable. The OPDP inquiry has not resulted in any penalties, fines, or enforcement action, and Penterra has not yet been required to undertake any remedial measures beyond the voluntary withdrawal of the cited materials. Accordingly, we do not believe that accrual of a loss contingency is required for the Q3 2023 interim period or, assuming the inquiry remains at its current stage, for the FY 2023 annual period.
Disclosure without accrual is required when a loss is reasonably possible (i.e., the chance of the future event occurring is more than remote but less than probable) and the amount or range of loss cannot be estimated, or when a loss is probable but the amount cannot be reasonably estimated. Given the materiality of Zelvara® to Penterra's revenue and the range of potential adverse outcomes — from a Warning Letter requiring corrective actions to a referral for enforcement action — we believe that a loss is, at minimum, reasonably possible. Accordingly, footnote disclosure of the contingent liability is likely required in both the Q3 2023 Form 10-Q and the FY 2023 Form 10-K financial statements.
B. Nature of Potential Losses
The potential losses that could arise from the OPDP inquiry fall into several categories:
• Monetary Penalties. If the inquiry escalates to a Warning Letter or enforcement action, Penterra could be subject to monetary penalties imposed by the FDA or, if the matter is referred to DOJ, civil monetary penalties or damages under the False Claims Act. At the current inquiry stage, no penalties have been imposed or sought, and the likelihood and amount of any future penalties cannot be reasonably estimated.
• Corrective Action Costs. If Penterra is required (or voluntarily elects) to undertake corrective actions, the associated costs could include: (a) preparation and dissemination of a Dear Healthcare Provider ("DHCP") letter to the approximately 42,000 physicians who received the email blast and to other prescribers who may have been exposed to the cited materials; (b) sales-force retraining, including development and delivery of updated training modules for Penterra's approximately 680 field sales representatives; and (c) revision of the PRC's standard operating procedures and compliance workflows.
• Promotional Agency Transition Costs. The Company is evaluating the termination of its engagement with Ridgeline Health Analytics LLC, the agency responsible for the Clarity Campaign, and the onboarding of a successor agency, Calloway & March Communications LLC. Transition costs — including early-termination fees under the Ridgeline Master Services Agreement, onboarding and creative development fees for Calloway & March, and the costs of reviewing and re-approving existing promotional materials — could be substantial, though the precise amounts are not yet known.
• Outside Counsel and Consulting Fees. The engagement of Calderwood & Harkness LLP (fee cap: $450,000), anticipated engagement of Whitfield Bauer & Associates LLP (fees to be determined), and engagement of Tavrenis Stern Consulting Group LLC (fixed fee: $87,500) represent direct costs attributable to the inquiry. These costs are reasonably estimable and, depending on their magnitude relative to Penterra's financial statements, may warrant separate disclosure.
• Revenue Impact. If the OPDP inquiry or any resulting enforcement action restricts Penterra's ability to promote Zelvara® — whether through a mandatory withdrawal of additional promotional materials, a prohibition on certain promotional claims, or a broader corrective advertising requirement — the resulting reduction in promotional activity could lead to a decline in new and renewal prescriptions, payer formulary coverage, or managed-care contracting terms. The potential revenue impact is inherently uncertain and cannot be reliably estimated at this time.
C. Recommended Coordination Steps
We recommend the following steps to ensure appropriate coordination with Meriden & Cole CPAs LLP regarding the contingent-liability considerations arising from the OPDP inquiry:
1. Initial Contact. Jeffrey Park or Audrey Zhou will contact Susan Nakamura, CPA, Engagement Partner at Meriden & Cole CPAs LLP (200 Park Avenue, New York, NY 10166), to inform her of the OPDP inquiry and to initiate a discussion regarding its potential impact on the Q3 2023 and FY 2023 financial-statement footnotes. This contact should be made promptly after the filing of the Form 8-K to ensure that Meriden & Cole is aware of the inquiry and can factor it into its audit planning.
2. Privilege-Conscious Information Sharing. In communicating with Meriden & Cole, care must be taken not to waive the attorney-client privilege or the work-product protection by over-disclosing the substance of the internal investigation or Calderwood & Harkness's legal analysis. We recommend providing Meriden & Cole with (a) a copy of the filed Form 8-K (which will be a public document), and (b) a brief, privilege-conscious summary of the nature and status of the inquiry, prepared by Calderwood & Harkness, that provides sufficient information for Meriden & Cole to perform its ASC 450 evaluation without revealing privileged communications or attorney mental impressions. This summary should be marked "Prepared at the Direction of Counsel — Subject to Attorney-Client Privilege" and should be reviewed by Leonard Cross before transmission.
3. Audit Committee Briefing. We recommend that Penterra's Audit Committee be briefed on the OPDP inquiry and its potential financial-statement implications at the earliest practicable meeting. The Audit Committee has oversight responsibility for the Company's financial reporting and internal controls, and awareness of the inquiry is necessary for the Committee to discharge its responsibilities effectively. Margaret Tan, in coordination with Leonard Cross, should prepare a presentation for the Audit Committee that covers the nature of the inquiry, the Company's response strategy, the securities-disclosure approach, and the potential ASC 450 implications. As with the auditor communication, the Audit Committee briefing should be conducted in a manner that preserves applicable privileges.
VII. FY 2023 Form 10-K Disclosure Recommendations
Penterra's FY 2023 Annual Report on Form 10-K, which we understand is anticipated to be filed with the SEC on or about February 28, 2024, will need to address the OPDP inquiry in several sections. The recommendations below are based on the facts known as of November 3, 2023, and may need to be updated as the inquiry progresses. Calderwood & Harkness will work with Penterra's in-house legal and financial-reporting teams to prepare the relevant disclosures in advance of the 10-K filing date.
A. Risk Factors (Item 1A)
Penterra's FY 2022 Form 10-K contains a risk factor regarding FDA regulatory compliance that states, in general terms, that the Company's products are subject to extensive regulation by the FDA and that the Company's promotional practices must comply with applicable laws and regulations. This risk factor should be updated in the FY 2023 10-K to specifically reference the OPDP inquiry and the risks it presents. We recommend adding or modifying risk-factor language to address the following points:
(a) Promotional-Practices Scrutiny by FDA. The Company received an OPDP inquiry letter in October 2023 regarding certain promotional materials for Zelvara®, and any failure to resolve the inquiry satisfactorily could result in adverse regulatory action, including the issuance of a Warning Letter, a requirement to undertake corrective actions (such as a DHCP letter or corrective advertising), restrictions on promotional claims, or referral to DOJ or OIG for potential enforcement action.
(b) Reliance on Zelvara® as a Material Revenue Contributor. Zelvara® is the Company's single largest revenue-generating product, representing approximately 37% of total revenue. Any regulatory action that restricts the Company's ability to promote or sell Zelvara® could have a material adverse effect on the Company's business, financial condition, and results of operations.
(c) Enforcement Risk. The OPDP inquiry could escalate to more serious regulatory actions, including a Warning Letter, a consent decree, or a referral to DOJ for civil or criminal prosecution. In addition, the inquiry could attract attention from state attorneys general, qui tam relators, or private plaintiffs, leading to additional legal proceedings and potential liability.
All risk-factor language should include appropriate forward-looking cautionary statements consistent with the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.
B. Legal Proceedings (Item 3)
The OPDP inquiry should be disclosed under the Legal Proceedings section of the FY 2023 10-K. The disclosure should include the following information:
• The date of the inquiry letter (October 12, 2023) and the date of receipt (October 16, 2023);
• The reference number (OPDP-2023-1847);
• The nature of the allegations, described in general terms: OPDP has raised questions regarding the adequacy of certain promotional materials for Zelvara®, including the substantiation of efficacy claims, the omission of risk information (specifically hepatotoxicity risk), the use of allegedly misleading graphical presentations (truncated y-axis bar charts), and the presentation of data from an unpublished, Company-funded study without adequate disclosure of sponsorship or study limitations;
• The Company's response: Penterra has voluntarily withdrawn the cited promotional materials, engaged outside counsel to conduct an internal review, and submitted a response to OPDP (once the response is submitted);
• The status of the inquiry as of the 10-K filing date.
If the inquiry has been resolved by the time of the 10-K filing — for example, if OPDP issues a close-out letter accepting Penterra's response and closing the inquiry without further action — the disclosure should reflect that favorable resolution, including the date and substance of the close-out letter. If the inquiry has escalated (e.g., to a Warning Letter), the disclosure should be updated accordingly.
C. Management's Discussion and Analysis (Item 7)
The MD&A section of the FY 2023 10-K should address any known or anticipated impact of the OPDP inquiry on Zelvara® revenue trends, promotional spending, and remediation costs. Specifically:
• If the inquiry has resulted in a material change to Penterra's promotional strategy for Zelvara® — such as the withdrawal of promotional materials, the suspension of specific promotional claims, or the transition from Ridgeline to a successor promotional agency — these developments should be discussed in the context of their potential impact on Zelvara® revenue and the Company's overall commercial performance.
• The costs of remediation — including outside counsel and consulting fees, corrective communications, sales-force retraining, and promotional agency transition — should be discussed to the extent they are material to the Company's financial results for FY 2023 or are expected to be material in future periods.
• If the inquiry has been resolved without a Warning Letter or enforcement action by the 10-K filing date, the MD&A disclosure can reflect that favorable outcome while noting ongoing compliance enhancements that the Company has implemented or plans to implement as a result of the internal review.
D. Financial-Statement Footnotes
The contingent-liability footnote disclosure in Penterra's FY 2023 audited financial statements should be coordinated with Meriden & Cole CPAs LLP consistent with the recommendations in Section VI above. The footnote should describe the nature of the OPDP inquiry in general terms and state the Company's assessment of the likelihood and amount of potential loss. Specifically:
• If a loss is not probable but is reasonably possible (as we believe to be the case at the current stage of the inquiry), the footnote should describe the nature of the contingency and state that the Company cannot currently estimate the amount or range of possible loss.
• If the matter has been resolved by the 10-K filing date, the footnote should state the resolution and disclose the actual costs incurred (legal fees, remediation costs, and any penalties or fines, if applicable).
• The footnote language should be consistent with the disclosures in the Risk Factors, Legal Proceedings, and MD&A sections of the 10-K to avoid internal inconsistencies that could invite SEC comment-letter scrutiny.
VIII. Impact on Penterra's Stock (NYSE: PTPH) and Market Considerations
Beyond the legal requirements for disclosure, Penterra should consider the practical market implications of the OPDP inquiry and the recommended disclosure strategy.
Penterra's approximate market capitalization of $6.9 billion means that even a modest percentage decline in the Company's stock price in response to public disclosure of the OPDP inquiry could represent hundreds of millions of dollars in lost shareholder value. A 3% decline, for example, would equate to approximately $207 million in lost market capitalization; a 5% decline would equate to approximately $345 million. While stock-price reactions are inherently unpredictable and depend on a range of factors beyond the Company's control — including broader market conditions, analyst sentiment, and the perceived severity of the regulatory risk — the potential magnitude of the impact underscores the importance of managing the disclosure carefully.
Proactive, transparent disclosure via the recommended Form 8-K filing mitigates the risk of a larger and more damaging stock-price decline from uncontrolled leaks, media reports, or FOIA disclosure. When a company discloses a regulatory development proactively and on its own terms — providing appropriate context, noting cooperative engagement with the regulator, and highlighting voluntary remedial actions — the market reaction is typically more muted than when the same information emerges through external channels in an uncontrolled manner. In the latter scenario, the market often reacts not only to the substance of the regulatory development but also to the perceived lack of transparency, which compounds the stock-price damage.
Prompt disclosure also reduces securities-litigation risk. Shareholder class-action lawsuits under Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5 thereunder, typically allege that the defendant company failed to disclose a known material risk, or that the company's prior public statements were materially misleading because they omitted information about the undisclosed regulatory development. By disclosing the OPDP inquiry promptly after receipt and initial assessment, Penterra significantly reduces its exposure to such claims. The disclosure establishes a public record that the Company identified and disclosed the material regulatory development in a timely manner, which undercuts the scienter element of a Section 10(b) claim and demonstrates good-faith compliance with the disclosure obligations.
If the OPDP inquiry is ultimately resolved without adverse enforcement action — which is a realistic possibility, particularly if Penterra responds cooperatively and implements appropriate corrective measures — the initial Form 8-K disclosure positions the Company to update the market with a favorable outcome. A supplemental 8-K filing or press release announcing the close-out of the inquiry could serve as a positive catalyst for the stock price, partially or fully reversing any initial decline. Conversely, if the Company fails to disclose the inquiry promptly and the matter later becomes public through other channels, the ability to present a favorable resolution narrative is significantly diminished.
IX. Recommendations Summary
Based on the foregoing analysis, we recommend the following actions:
1. Form 8-K Filing. Penterra should file a Current Report on Form 8-K under Item 8.01 ("Other Events") by November 6, 2023, disclosing receipt of the OPDP inquiry letter (reference OPDP-2023-1847) and the Company's voluntary withdrawal of the cited promotional materials. The 8-K should include appropriate cautionary language, forward-looking statements safe-harbor boilerplate, and a statement regarding the Company's cooperation with the inquiry, as outlined in Section V.B of this memorandum.
2. Regulation FD Compliance. Margaret Tan should immediately issue an internal directive restricting discussion of the OPDP inquiry by Penterra personnel pending the filing of the Form 8-K. The directive should specifically address Derek Foss (VP, Commercial Operations & Marketing), the investor-relations team, and any other personnel who may interact with securities analysts, institutional investors, or other market professionals. All analyst and investor communications should be monitored for compliance with Regulation FD until the 8-K is filed.
3. Auditor Coordination. Jeffrey Park or Audrey Zhou will contact Susan Nakamura, CPA, Engagement Partner at Meriden & Cole CPAs LLP, to discuss the OPDP inquiry and its potential impact on the contingent-liability footnote disclosures in Penterra's Q3 2023 Form 10-Q and FY 2023 Form 10-K financial statements, consistent with the recommendations in Section VI of this memorandum.
4. Audit Committee Briefing. Penterra's Audit Committee should be briefed on the OPDP inquiry, the Company's response strategy, the recommended securities-disclosure approach, and the potential ASC 450 implications at the earliest practicable Audit Committee meeting. Margaret Tan, in coordination with Leonard Cross at Calderwood & Harkness, should prepare the briefing materials.
5. FY 2023 10-K Preparation. Penterra should update the risk factors (Item 1A), legal-proceedings disclosures (Item 3), MD&A commentary (Item 7), and financial-statement footnotes in its FY 2023 Annual Report on Form 10-K (anticipated filing date: February 28, 2024) to reflect the OPDP inquiry and, if resolved by that date, its resolution. Calderwood & Harkness will work with Pen